Sector News

David Apelian jumps ship from Achillion

December 18, 2017
Life sciences

David Apelian, M.D., Ph.D., has handed in his notice as EVP and chief medical officer at Achillion.

In a brief SEC filing, the biotech said he had “delivered his resignation […] effective December 28, 2017.”

The brief update said he was leaving to “pursue another professional opportunity,” though that was all she wrote on details. A retained search for a new CMO has begun, with help from Russell Reynolds Associates.

This comes three months after Janssen, the biotech unit of Johnson & Johnson, said it was ditching work with Achillion on a cocktail hep C program, citing a crowded market of innovative meds in this area, namely those from Gilead.

Achillion, with a market cap of around $400 million, was hit hard by the decision as the biotech was working with Janssen on its NS5A inhibitor, odalasvir, for this program in a potential $1 billion biobucks deal before the plug was pulled.

Some had seen Gilead or J&J as potential buyers of the company, but this has not come to fruition, and its shares have taken a hit since J&J’s decision to terminate its hep C deal.

Achillion is also now working on a midstage med, ACH-4471, in patients with untreated paroxysmal nocturnal hemoglobinuria (PNH).

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach